JP2022521183A5 - - Google Patents

Info

Publication number
JP2022521183A5
JP2022521183A5 JP2021547444A JP2021547444A JP2022521183A5 JP 2022521183 A5 JP2022521183 A5 JP 2022521183A5 JP 2021547444 A JP2021547444 A JP 2021547444A JP 2021547444 A JP2021547444 A JP 2021547444A JP 2022521183 A5 JP2022521183 A5 JP 2022521183A5
Authority
JP
Japan
Prior art keywords
polynucleotide
antigen
antibody
vector
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021547444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521183A (ja
JP7603013B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018806 external-priority patent/WO2020172259A1/en
Publication of JP2022521183A publication Critical patent/JP2022521183A/ja
Publication of JP2022521183A5 publication Critical patent/JP2022521183A5/ja
Priority to JP2024214374A priority Critical patent/JP2025026612A/ja
Application granted granted Critical
Publication of JP7603013B2 publication Critical patent/JP7603013B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021547444A 2019-02-20 2020-02-19 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー Active JP7603013B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024214374A JP2025026612A (ja) 2019-02-20 2024-12-09 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962808264P 2019-02-20 2019-02-20
US62/808,264 2019-02-20
PCT/US2020/018806 WO2020172259A1 (en) 2019-02-20 2020-02-19 Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024214374A Division JP2025026612A (ja) 2019-02-20 2024-12-09 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー

Publications (3)

Publication Number Publication Date
JP2022521183A JP2022521183A (ja) 2022-04-06
JP2022521183A5 true JP2022521183A5 (https=) 2023-03-02
JP7603013B2 JP7603013B2 (ja) 2024-12-19

Family

ID=72144760

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547444A Active JP7603013B2 (ja) 2019-02-20 2020-02-19 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー
JP2024214374A Pending JP2025026612A (ja) 2019-02-20 2024-12-09 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024214374A Pending JP2025026612A (ja) 2019-02-20 2024-12-09 がんを標的とする、ウイルスによってコードされる、調節可能なｔ（ｃａｔｖｅｒｔ）またはｎｋ細胞（ｃａｔｖｅｒｎ）リンカー

Country Status (11)

Country Link
US (1) US20220257760A1 (https=)
EP (1) EP3927750A4 (https=)
JP (2) JP7603013B2 (https=)
KR (1) KR20210128399A (https=)
CN (1) CN113646334B (https=)
AU (1) AU2020226524A1 (https=)
BR (1) BR112021015907A2 (https=)
CA (1) CA3129506A1 (https=)
IL (2) IL325850A (https=)
SG (1) SG11202108924RA (https=)
WO (1) WO2020172259A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
CN115124625B (zh) * 2021-03-24 2024-11-26 圣安生医股份有限公司 免疫调节及抗肿瘤相关纳米抗体、其核酸编码序列及应用
CN112794916B (zh) * 2021-04-08 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用
JP2024516168A (ja) * 2021-04-22 2024-04-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド がんを治療するための組成物および方法
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
JP2023176123A (ja) * 2022-05-31 2023-12-13 株式会社 光バイオ ウイルスベクター及びそれを含むがん細胞増殖抑制剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526243A (ja) * 1997-12-23 2001-12-18 セル ジェネシス インコーポレイテッド 複数のアデノ随伴ウイルスベクターを使用する、複数の遺伝子の細胞への送達
US6221349B1 (en) * 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
JP2006129811A (ja) * 2004-11-08 2006-05-25 Hitachi Ltd 試料核酸の分析方法、分析装置および分析キット
US7879992B2 (en) * 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
US20100305002A1 (en) * 2009-04-27 2010-12-02 Roswell Park Cancer Institute Reagents and Methods for Producing Bioactive Secreted Peptides
EP2327793A1 (en) * 2009-11-25 2011-06-01 Universität Zu Köln Pyrosequencing method for predicting the response of a patient towards anti cancer treatment
CN105530959B (zh) * 2013-03-15 2021-09-17 纪念斯隆-凯特琳癌症中心 多聚化技术
EP3146051B8 (en) * 2014-05-20 2019-11-27 University of Iowa Research Foundation Huntington's disease therapeutic compounds
EP3204503A1 (en) * 2014-10-06 2017-08-16 Arthrogen BV Aav-based gene therapy
CN104592395B (zh) * 2015-01-27 2017-11-14 中国药科大学 Vegfr2单链抗体与mica融合蛋白的制备方法及用途
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
GB201516066D0 (en) * 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
CN108472365A (zh) * 2015-10-30 2018-08-31 艾丽塔生物治疗剂公司 用于肿瘤转导的组合物和方法
FR3043914B1 (fr) * 2015-11-23 2017-12-29 Univ Limoges Utilisation d'oligonucleotides antisens pour produire des ig tronquees par saut d'exon pour le traitement de maladies impliquant des cellules de la lignee b.
CA3020633A1 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
CA3021634A1 (en) * 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
US20180126003A1 (en) * 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
IL303187A (en) * 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
WO2018120842A1 (zh) * 2016-12-30 2018-07-05 上海欣百诺生物科技有限公司 一种双功能分子及其应用
JP7216668B2 (ja) * 2017-05-26 2023-02-01 エピセントアールエックス，インコーポレイテッド 導入遺伝子を保持する組換えアデノウイルス
EP3864161A4 (en) * 2018-10-09 2022-11-23 The University of North Carolina at Chapel Hill Regulated gene editing system

Similar Documents

Publication Publication Date Title
JP2022521183A5 (https=)
EP2964675B1 (en) Engager cells for immunotherapy
Zhou et al. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft
CN109280086B (zh) 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体
CN108440674A (zh) 一种Trop-2特异性嵌合抗原受体细胞制备及其用途
US11723922B2 (en) CXCR6-transduced T cells for targeted tumor therapy
Lo et al. Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor
JP2022525925A5 (https=)
Hänsch et al. Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma
WO2024119768A9 (zh) 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用
Vyas et al. Mono-and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia
King et al. Advances in tumour immunotherapy
JP2022543059A5 (https=)
WO2019243888A9 (en) Compositions and methods for making engineered t cells
Hojjatipour et al. Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells
JP2022543058A5 (https=)
JP2022543060A5 (https=)
CN116239692B (zh) 分离的抗体、包含该抗体的car及其用途
CN111732665A (zh) 一种靶向表达癌胚抗原的细胞的嵌合抗原受体
CN119431605B (zh) 加载自杀基因的安全可控型嵌合抗原受体、表达其的巨噬细胞及应用
CN117683113B (zh) 表达mIL-15的HER2靶向CAR-NK细胞的制备及其应用
CN119798464B (zh) 一种靶向cd19和bcma双靶点的嵌合抗原受体及其应用
CN113801228B (zh) 靶向cd38的单链抗体、全人源嵌合抗原受体、制备方法和应用
CN119432754B (zh) 表达gm-csf的连续截短功能区的免疫工程细胞及应用
CN113929785B (zh) 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用